Revvity, Inc. Common Stock RVTY 深 滬
已收盤 08-01 16:00:00 美东时间
88.23
+0.330
+0.38%
華盛通- 最 高88.35
- 今 開87.02
- 成交量 160.11万股
- 最 低 85.80
- 昨 收 87.90
- 總市值 104.11亿
- 52周最高 129.29
- 市盈率 靜 36.63
- 換手率 1.36%
- 52周最低 85.80
- 委 比 -89.47%
- 總股本 1.18亿
- 歷史最高 202.11
- 量 比 0.65
- 振 幅 2.90%
- 歷史最低 14.16
- 每 手 1
- 風險率 11.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Stifel Maintains Hold on Revvity, Lowers Price Target to $110
Stifel analyst Daniel Arias maintains Revvity (NYSE:RVTY) with a Hold and lowers the price target from $120 to $110.
07-29 21:21
Revvity Slashes Outlook As China Policy Deals Diagnostics Blow
Revvity beat Q2 earnings estimates but cut its 2025 profit outlook as China policy changes hit its immunodiagnostics business.
07-28 23:51
Revvity Lowers FY2025 Adj EPS Guidance from $4.90-$5.00 to $4.85-$4.95 vs $4.93 Est; Raises FY2025 Sales Guidance from $2.830B-$2.870B to $2.840B-$2.880B vs $2.852B Est
For the full year 2025, the Company is raising its full year revenue guidance to $2.84-$2.88 billion to reflect recent changes in foreign currency exchange rates and assumes 2% to 4% organic growth. The Company is also
07-28 18:02
Earnings Scheduled For July 28, 2025
Companies Reporting Before The Bell • Bank of Hawaii (NYSE:BOH) is likely to re...
07-28 16:32
Here are the major earnings before the open Monday
Major earnings expected before the bell on Monday include: Enterprise Products Partners L.P. (EPD) Rithm Capital Corp. (RITM) Alliance Resource Partners, L.P. (ARLP) New Gold (NGD) Revvity (RVTY) Othe...
07-28 06:00
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor
Revolution Medicines announced the publication of a research paper in *Science* detailing zoldonrasib (RMC-9805), a RAS(ON) G12D-selective covalent inhibitor targeting oncogenic RAS G12D mutations. These mutations are common in cancers like pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. Zoldonrasib leverages a novel mechanism involving a protein-protein interface to selectively inhibit RAS G12D, showing promi...
07-24 20:00
Evercore ISI Group Maintains Outperform on Revvity, Lowers Price Target to $115
Evercore ISI Group analyst Vijay Kumar maintains Revvity (NYSE:RVTY) with a Outperform and lowers the price target from $116 to $115.
07-08 21:05
美股大行评级 | 潜在涨幅205.56%！康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德：维持HIVE Digital Technologies(HIVE)"超配"评级，目标价从5美元升至5.5美元</p> <p>• BTIG：维持Theravance Biopharma(TBPH)"买入"评
06-28 08:37
美股大行评级 | 潜在涨幅61.27%！Loop Capital上调英伟达目标价至250美元，维持"买入"评级
今日重点评级关注：Benchmark：维持特斯拉(TSLA)"买入"评级，目标价从350美元升至475美元>>
06-27 08:37
What 9 Analyst Ratings Have To Say About Revvity
In the last three months, 9 analysts have published ratings on Revvity (NYSE:RV...
06-27 03:00
公司簡介
公司名稱
|
Revvity, Inc.
|
行業分類
|
Medical Specialties
|
業務描述
|
Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The firm operates through the following segments: Life Sciences and Diagnostics. The Life Sciences segment delivers innovative solutions to optimize workflows, boost productivity, and accelerate drug discovery and development. The Diagnostics segment provides instruments, reagents, assay platforms, and software to healthcare and research professionals, with a focus on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics to enhance patient outcomes. Revvity was founded on April 19, 1937 and is headquartered in Waltham, MA.
|
Stifel Maintains Hold on Revvity, Lowers Price Target to $110
Stifel analyst Daniel Arias maintains Revvity (NYSE:RVTY) with a Hold and lowers the price target from $120 to $110.
07-29 21:21
Revvity Slashes Outlook As China Policy Deals Diagnostics Blow
Revvity beat Q2 earnings estimates but cut its 2025 profit outlook as China policy changes hit its immunodiagnostics business.
07-28 23:51
Revvity Lowers FY2025 Adj EPS Guidance from $4.90-$5.00 to $4.85-$4.95 vs $4.93 Est; Raises FY2025 Sales Guidance from $2.830B-$2.870B to $2.840B-$2.880B vs $2.852B Est
For the full year 2025, the Company is raising its full year revenue guidance to $2.84-$2.88 billion to reflect recent changes in foreign currency exchange rates and assumes 2% to 4% organic growth. The Company is also
07-28 18:02
Earnings Scheduled For July 28, 2025
Companies Reporting Before The Bell • Bank of Hawaii (NYSE:BOH) is likely to re...
07-28 16:32
Here are the major earnings before the open Monday
Major earnings expected before the bell on Monday include: Enterprise Products Partners L.P. (EPD) Rithm Capital Corp. (RITM) Alliance Resource Partners, L.P. (ARLP) New Gold (NGD) Revvity (RVTY) Othe...
07-28 06:00
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor
Revolution Medicines announced the publication of a research paper in *Science* detailing zoldonrasib (RMC-9805), a RAS(ON) G12D-selective covalent inhibitor targeting oncogenic RAS G12D mutations. These mutations are common in cancers like pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. Zoldonrasib leverages a novel mechanism involving a protein-protein interface to selectively inhibit RAS G12D, showing promi...
07-24 20:00
Evercore ISI Group Maintains Outperform on Revvity, Lowers Price Target to $115
Evercore ISI Group analyst Vijay Kumar maintains Revvity (NYSE:RVTY) with a Outperform and lowers the price target from $116 to $115.
07-08 21:05
美股大行评级 | 潜在涨幅205.56%！康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德：维持HIVE Digital Technologies(HIVE)"超配"评级，目标价从5美元升至5.5美元</p> <p>• BTIG：维持Theravance Biopharma(TBPH)"买入"评
06-28 08:37
美股大行评级 | 潜在涨幅61.27%！Loop Capital上调英伟达目标价至250美元，维持"买入"评级
今日重点评级关注：Benchmark：维持特斯拉(TSLA)"买入"评级，目标价从350美元升至475美元>>
06-27 08:37
What 9 Analyst Ratings Have To Say About Revvity
In the last three months, 9 analysts have published ratings on Revvity (NYSE:RV...
06-27 03:00
派息除權日
|
每股總股息
| 派息日期 |
2025-10-17
|
0.07
|
2025-11-07
|
2025-07-18
|
0.07
|
2025-08-08
|
2025-04-17
|
0.07
|
2025-05-09
|
2025-01-17
|
0.07
|
2025-02-07
|
2024-10-18
|
0.07
|
2024-11-08
|
2024-07-19
|
0.07
|
2024-08-09
|
2024-04-18
|
0.07
|
2024-05-10
|
2024-01-18
|
0.07
|
2024-02-09
|
2023-10-19
|
0.07
|
2023-11-10
|
2023-07-20
|
0.07
|
2023-08-11
|
2023-04-20
|
0.07
|
2023-05-12
|
2023-01-19
|
0.07
|
2023-02-10
|
2022-10-20
|
0.07
|
2022-11-11
|
2022-07-21
|
0.07
|
2022-08-12
|
2022-04-21
|
0.07
|
2022-05-13
|
2022-01-20
|
0.07
|
2022-02-11
|
2021-10-21
|
0.07
|
2021-11-12
|
2021-07-15
|
0.07
|
2021-08-06
|
2021-04-15
|
0.07
|
2021-05-07
|
2021-01-21
|
0.07
|
2021-02-12
|
2020-10-15
|
0.07
|
2020-11-06
|
2020-07-16
|
0.07
|
2020-08-07
|
2020-04-16
|
0.07
|
2020-05-08
|
2020-01-16
|
0.07
|
2020-02-07
|
2019-10-17
|
0.07
|
2019-11-08
|
2019-07-18
|
0.07
|
2019-08-09
|
2019-04-17
|
0.07
|
2019-05-10
|
2019-01-17
|
0.07
|
2019-02-08
|
2018-10-18
|
0.07
|
2018-11-09
|
2018-07-19
|
0.07
|
2018-08-10
|
2018-04-12
|
0.07
|
2018-05-10
|
2018-01-18
|
0.07
|
2018-02-09
|
2017-10-19
|
0.07
|
2017-11-10
|
2017-07-19
|
0.07
|
2017-08-10
|
2017-04-11
|
0.07
|
2017-05-10
|
2017-01-18
|
0.07
|
2017-02-10
|
2016-10-12
|
0.07
|
2016-11-10
|
2016-07-13
|
0.07
|
2016-08-10
|
2016-04-13
|
0.07
|
2016-05-10
|
2016-01-13
|
0.07
|
2016-02-10
|
2015-10-14
|
0.07
|
2015-11-10
|
2015-07-15
|
0.07
|
2015-08-10
|
2015-04-15
|
0.07
|
2015-05-11
|
2015-01-14
|
0.07
|
2015-02-06
|
2014-10-15
|
0.07
|
2014-11-07
|
2014-07-16
|
0.07
|
2014-08-08
|
2014-04-15
|
0.07
|
2014-05-09
|
2014-01-15
|
0.07
|
2014-02-07
|
2013-10-16
|
0.07
|
2013-11-08
|
2013-07-17
|
0.07
|
2013-08-09
|
2013-04-17
|
0.07
|
2013-05-10
|
2013-01-16
|
0.07
|
2013-02-08
|
2012-10-17
|
0.07
|
2012-11-09
|
2012-07-18
|
0.07
|
2012-08-10
|
2011-07-20
|
0.07
|
2011-08-12
|
2011-04-19
|
0.07
|
2011-05-13
|
2011-01-19
|
0.07
|
2011-02-11
|
2010-10-20
|
0.07
|
2010-11-12
|
2010-07-21
|
0.07
|
2010-08-13
|
2010-04-14
|
0.07
|
2010-05-07
|
2010-01-20
|
0.07
|
2010-02-12
|
2009-10-21
|
0.07
|
2009-11-13
|
2009-07-15
|
0.07
|
2009-08-07
|
2009-04-15
|
0.07
|
2009-05-08
|
2009-01-14
|
0.07
|
2009-02-06
|
2008-10-15
|
0.07
|
2008-11-07
|
2008-07-16
|
0.07
|
2008-08-08
|
2008-04-16
|
0.07
|
2008-05-09
|
2008-01-16
|
0.07
|
2008-02-08
|
2007-10-17
|
0.07
|
2007-11-09
|
2007-07-18
|
0.07
|
2007-08-10
|
2007-04-18
|
0.07
|
2007-05-11
|
2007-01-17
|
0.07
|
2007-02-09
|
2006-10-18
|
0.07
|
2006-11-10
|
2006-07-19
|
0.07
|
2006-08-11
|
2006-04-19
|
0.07
|
2006-05-12
|
2006-01-18
|
0.07
|
2006-02-10
|
2005-10-19
|
0.07
|
2005-11-11
|
2005-07-20
|
0.07
|
2005-08-12
|
2005-04-20
|
0.07
|
2005-05-13
|
2005-01-19
|
0.07
|
2005-02-11
|
2004-10-20
|
0.07
|
2004-11-12
|
2004-07-21
|
0.07
|
2004-08-13
|
2004-04-21
|
0.07
|
2004-05-14
|
2004-01-14
|
0.07
|
2004-02-05
|
2003-10-15
|
0.07
|
2003-11-07
|
2003-07-16
|
0.07
|
2003-08-08
|
2003-04-15
|
0.07
|
2003-05-09
|
2003-01-15
|
0.07
|
2003-02-07
|
2002-10-16
|
0.07
|
2002-11-08
|
2002-07-17
|
0.07
|
2002-08-09
|
2002-04-17
|
0.07
|
2002-05-10
|
2002-01-16
|
0.07
|
2002-02-09
|
2001-10-17
|
0.07
|
2001-11-09
|
2001-07-18
|
0.07
|
2001-08-10
|
2001-04-18
|
0.14
|
2001-05-10
|
2001-01-17
|
0.14
|
2001-02-09
|
2000-10-18
|
0.14
|
2000-11-10
|
2000-07-19
|
0.14
|
2000-08-10
|
2000-04-18
|
0.14
|
2000-05-10
|
2000-01-19
|
0.14
|
2000-02-10
|
1999-10-20
|
0.14
|
1999-11-10
|
1999-07-21
|
0.14
|
1999-08-10
|
1999-04-21
|
0.14
|
1999-05-10
|
1999-01-20
|
0.14
|
1999-02-10
|
1998-10-21
|
0.14
|
1998-11-10
|
1998-07-22
|
0.14
|
1998-08-10
|
1998-04-15
|
0.14
|
1998-05-08
|
1998-01-14
|
0.14
|
1998-02-06
|
1997-10-15
|
0.14
|
1997-11-10
|
1997-07-16
|
0.14
|
1997-08-08
|
1997-04-16
|
0.14
|
1997-05-09
|
1997-01-15
|
0.14
|
1997-02-10
|
1996-10-16
|
0.14
|
1996-11-08
|
1996-07-17
|
0.14
|
1996-08-09
|
1996-04-17
|
0.14
|
1996-05-10
|
1996-01-17
|
0.14
|
1996-02-09
|
1995-10-18
|
0.14
|
1995-11-10
|
1995-07-19
|
0.14
|
1995-08-10
|
1995-04-17
|
0.14
|
1995-05-10
|
1995-02-14
|
0.010
|
1995-02-14
|
1995-01-13
|
0.14
|
1995-02-10
|
1994-10-17
|
0.14
|
1994-11-10
|
1994-07-18
|
0.14
|
1994-08-10
|
1994-04-18
|
0.14
|
1994-05-10
|
1994-01-14
|
0.14
|
1994-02-10
|
1993-10-18
|
0.13
|
1993-11-10
|
1993-07-19
|
0.13
|
1993-08-10
|
1993-04-12
|
0.13
|
1993-05-07
|
1993-01-15
|
0.13
|
1993-02-10
|
1992-10-19
|
0.13
|
1992-11-10
|
1992-07-13
|
0.13
|
1992-08-07
|
1992-04-10
|
0.25
|
1992-05-08
|
1992-01-13
|
0.23
|
1992-02-07
|
1991-10-11
|
0.21
|
1991-11-08
|
1991-07-15
|
0.21
|
1991-08-09
|
1991-04-15
|
0.21
|
1991-05-10
|
1991-01-14
|
0.21
|
1991-02-08
|
1990-10-15
|
0.19
|
1990-11-09
|
1990-07-16
|
0.19
|
1990-08-10
|
1990-04-16
|
0.19
|
1990-05-10
|
1990-01-12
|
0.19
|
1990-02-09
|
1989-10-16
|
0.17
|
1989-11-10
|
1989-07-17
|
0.17
|
1989-08-10
|
1989-04-17
|
0.17
|
1989-05-10
|
1989-01-13
|
0.17
|
1989-02-10
|
1988-10-25
|
0.15
|
1988-11-10
|
1988-07-18
|
0.15
|
1988-08-10
|
1988-04-18
|
0.15
|
1988-05-10
|
1988-01-15
|
0.15
|
1988-02-10
|
1987-10-19
|
0.14
|
1987-11-10
|
1987-07-20
|
0.14
|
1987-08-07
|
1987-04-10
|
0.14
|
1987-05-08
|
1987-01-16
|
0.14
|
1987-02-10
|
1986-10-10
|
0.13
|
1986-11-07
|
1986-07-14
|
0.13
|
1986-08-08
|
1986-04-14
|
0.13
|
1986-05-09
|
1986-01-13
|
0.13
|
1986-02-07
|
1985-10-11
|
0.12
|
1985-11-08
|
1985-07-15
|
0.12
|
1985-08-09
|
1985-04-15
|
0.12
|
1985-05-10
|
1985-01-14
|
0.12
|
1985-02-08
|
1984-10-15
|
0.10
|
1984-11-09
|
1984-07-16
|
0.10
|
1984-08-10
|
1984-04-13
|
0.10
|
1984-05-10
|
1984-01-16
|
0.10
|
1984-02-10
|
1983-10-17
|
0.09
|
1983-11-10
|
1983-07-18
|
0.09
|
1983-08-10
|
1983-04-18
|
0.09
|
1983-05-10
|
1983-01-17
|
0.09
|
1983-02-10
|
1982-10-18
|
0.08
|
1982-11-10
|
1982-07-12
|
0.08
|
1982-08-02
|
1982-04-12
|
0.08
|
1982-05-03
|
1982-01-04
|
0.16
|
1982-01-08
|
1981-10-09
|
0.13
|
1981-11-02
|
1981-07-13
|
0.13
|
1981-08-03
|
1981-04-10
|
0.13
|
1981-05-01
|
1981-01-12
|
0.13
|
1981-02-02
|
1980-10-10
|
0.10
|
1980-11-03
|
1980-07-14
|
0.10
|
1980-08-01
|
1980-04-07
|
0.10
|
1980-05-01
|
1980-01-07
|
0.20
|
1980-02-01
|
1979-10-05
|
0.15
|
1979-11-01
|
1979-07-09
|
0.15
|
1979-08-01
|
1979-04-06
|
0.15
|
1979-05-01
|
1979-01-08
|
0.15
|
1979-02-01
|
1978-10-06
|
0.11
|
1978-11-01
|
1978-07-10
|
0.11
|
1978-08-01
|
1978-04-10
|
0.11
|
1978-05-01
|
1978-01-09
|
0.09
|
1978-02-01
|
1977-10-07
|
0.09
|
1977-11-01
|
1977-08-08
|
0.09
|
1977-09-01
|
1977-05-09
|
0.09
|
1977-06-01
|
